NEW YORK (GenomeWeb News) – CombiMatrix reported after the close of the market on Wednesday that its third-quarter revenues slipped around 4 percent year over year, with the decline coming mainly from soft government contracts and product sales.

CombiMatrix brought in total revenues of $970,000 for the three-month period ended Sept. 30, compared to $1 million in the year-ago period.

Revenues for the Mukilteo, Wash.-based company from government contracts fell to $133,000 from $343,000, while revenues from products sales rose to $250,000 from $158,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.